<?xml version="1.0" encoding="UTF-8"?>
<p>Management options for PTLD include reduction of immune suppression, biological therapy with anti-B cell antibodies, combination chemotherapy, and adoptive immunotherapy using EBV-specific CTLs [
 <xref ref-type="bibr" rid="CR41">41</xref>]. Surgery may be considered for localized PTLDs. Reduction of immune suppression alone results in clinical remission in 25–63 % of adults and in 40–86 % of pediatric PTLD patients by restoring EBV-specific immunity [
 <xref ref-type="bibr" rid="CR39">39</xref>]. These patients should be monitored closely for acute allograft rejection. Newer immunosuppressants, including mycophenolate mofetil and sirolimus, appear to be associated with fewer post-transplant malignancies.
</p>
